Breast pain and mammographic density increase as a consequence of raloxifene therapy

Journal of Endocrinological Investigation

Volumn 25, Issue 6, 2002, Pages 564-566

  Christodoulakos, George ^a   Lambrinoudaki, I V ^a   Vourtsi, A D ^b   Panoulis, K P ^a   Creatsas, G C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Center of Radiation Oncology   (Greece)

Author keywords

Breast density; Mammography; Raloxifene; SERM

Indexed keywords

ALENDRONIC ACID; CALCIUM; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ANAMNESIS; ARTICLE; DENSITY; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTALGIA; MEDICAL EXAMINATION; OSTEOPENIA; POSTMENOPAUSE; REFERENCE VALUE; BREAST; CASE REPORT; METABOLIC BONE DISEASE; MIDDLE AGED; PAIN; PATHOLOGY;

BONE DISEASES, METABOLIC; BREAST; CASE REPORT; FEMALE; HUMAN; MAMMOGRAPHY; MIDDLE AGE; PAIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; HUMANS; MIDDLE AGED;

EID: 0035987938     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345502     Document Type: Article

References (5)

1. Tamoxifen and mammographic breast densities
2. Can tamoxifen cause a significant mammographic density change in breast parenchyma?
3. Effect of tamoxifen on mammographic density
4. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation
5. Digitized mammography: A clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen or placebo